Harmony Biosciences Holdings, Inc. (HRMY) — Financial statements
Income statement, balance sheet, and cash flow for Harmony Biosciences Holdings, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 868↑21.5% | 715↑22.8% | 582↑32.9% | 438↑43.4% | 305 | |
| Cost of Revenue | 198↑26.5% | 157↑29.3% | 121↑45.2% | 83↑50.4% | 56 | |
| Gross Profit | 670↑20.1% | 558↑21.1% | 461↑30.0% | 354↑41.8% | 250 | |
| Operating Expenses | ||||||
| R&D Expenses | 190↑30.0% | 146↑91.7% | 76↑7.3% | 71↑133.4% | 30 | |
| General & Administrative Expenses | 153↑38.2% | 110↑15.8% | 95↑13.4% | 84↑31.5% | 64 | |
| Selling & Marketing Expenses | 120↑7.8% | 111↑13.9% | 97↑22.9% | 79↑16.4% | 68 | |
| SG&A Expenses | 272↑22.9% | 221↑14.8% | 193↑18.0% | 163↑23.7% | 132 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 462↑25.8% | 367↑36.6% | 269↑14.8% | 234↑44.2% | 162 | |
| Total Costs & Expenses | 660↑26.0% | 524↑34.3% | 390↑22.8% | 318↑45.8% | 218 | |
| Operating Results | ||||||
| Operating Income | 208↑9.2% | 191↓0.6% | 192↑59.8% | 120↑37.3% | 88 | |
| Depreciation & Amortization | 25↑5.1% | 24↓1.0% | 24↑4.2% | 23↑24.1% | 19 | |
| EBITDA | 255↑9.3% | 233↑5.4% | 222↑50.8% | 147↑82.5% | 80 | |
| EBIT | 230↑9.8% | 209↑6.2% | 197↑59.7% | 123↑100.4% | 62 | |
| Interest & Other Income | ||||||
| Net Interest Income | 7↑595.5% | 1↑111.6% | -9↑42.4% | -16↑34.6% | -24 | |
| Interest Income | 22↑18.2% | 19↑25.9% | 15↑371.2% | 3↑1295.5% | 0.22 | |
| Interest Expense | 15↓16.3% | 17↓26.4% | 24↑26.4% | 19↓22.3% | 24 | |
| Non-Operating Income | -21↓15.0% | -18↓260.6% | -5↓55.5% | -3↓112.7% | 26 | |
| Other Income / Expenses | 7↑574.3% | 0.98↑105.2% | -19↓20.2% | -16↑69.1% | -50 | |
| Income Before Tax | 215↑12.1% | 192↑10.6% | 173↑65.6% | 105↑179.7% | 37 | |
| Income Tax Expense | 56↑21.7% | 46↑4.0% | 45↑158.0% | -77↓2812.2% | 3 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 159↑9.1% | 145↑12.9% | 129↓29.0% | 181↑424.5% | 35 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 159↑9.1% | 145↑12.9% | 129↓29.0% | 181↑424.5% | 35 | |
| Bottom-Line Net Income | 159↑9.1% | 145↑12.9% | 129↓29.0% | 181↑424.5% | 35 | |
| EPS (Basic) | 2.76↑7.8% | 2.56↑18.0% | 2.17↓29.3% | 3.07↑411.7% | 0.60 | |
| EPS (Diluted) | 2.71↑8.0% | 2.51↑17.8% | 2.13↓28.3% | 2.97↑412.1% | 0.58 | |
| Weighted Average Shares | 57↑1.1% | 57↓4.3% | 59↑0.5% | 59↑2.9% | 58 | |
| Weighted Average Diluted Shares | 59↑1.2% | 58↓4.1% | 60↓1.2% | 61↑3.2% | 59 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.